摘要
目的:分析原发性肝癌(PLC)患者血清中p16启动子区域甲基化的改变状况及其临床意义。方法:运用甲基化特异性PCR技术,检测64例PLC患者血清p16基因启动子区域甲基化的改变情况,并分析与临床病理资料的关系。结果:PLC患者血清p16基因甲基化检出率为76.6%(49/64),而正常对照组和良性肝病组患者血清未检出p16基因甲基化,p16基因甲基化检出率与乙型肝炎表面抗原(HBsAg)、甲胎蛋白(AFP)、疾病分期及转移状态无明显关系。结论:p16基因检出启动子区域异常甲基化是PLC早期辅助诊断的分子标记物之一。
Objective:To analyze the aberrant methylation of p16 gene in sera from primary liver cancer patients and to evaluate the clinical significance. Methods:A methylation-specific PCR was performed for the detection of promoter hypermethylation of p16 gene in blood DNA from 64 cases of PLC patients,and to anamyze the relationship between the aberrant methylation of p16 gene and the clinical pathological data . Results:76.6%(49/64)of the sera from 64 cases of PLC patients showed hypermethylation for p16 promoter,whereas no methylated p16 gene promoter were found in sera from liver benign diseases patients and normal control. Methylated p16 gene promoter in sera did not strongly correlated with HBsAg, AFP,stage ,metastasis and differentiation in PLC. Conclusion:Detection of the aberrant methylation of p16 gene in blood DNA from PLC patients might offer an effective means for the earlier auxillary diagnosis of the malignancy.
出处
《医学研究生学报》
CAS
2005年第7期582-584,共3页
Journal of Medical Postgraduates
基金
南京军区南京总医院科研基金重点资助项目(批准号:2003017)
